DK1864668T3 - Anvendelse af prodrug til okulær, intravitreal administration - Google Patents

Anvendelse af prodrug til okulær, intravitreal administration

Info

Publication number
DK1864668T3
DK1864668T3 DK06290902.3T DK06290902T DK1864668T3 DK 1864668 T3 DK1864668 T3 DK 1864668T3 DK 06290902 T DK06290902 T DK 06290902T DK 1864668 T3 DK1864668 T3 DK 1864668T3
Authority
DK
Denmark
Prior art keywords
prodrug
ocular
application
intravitreal administration
intravitreal
Prior art date
Application number
DK06290902.3T
Other languages
English (en)
Inventor
Laura Rabinovich-Guilatt
Gregory Lambert
Original Assignee
Novagali Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novagali Pharma Sa filed Critical Novagali Pharma Sa
Application granted granted Critical
Publication of DK1864668T3 publication Critical patent/DK1864668T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Materials For Medical Uses (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK06290902.3T 2006-06-01 2006-06-01 Anvendelse af prodrug til okulær, intravitreal administration DK1864668T3 (da)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US11/444,337 US20070281914A1 (en) 2006-06-01 2006-06-01 Use of a steroid prodrug for the treatment of disease of the posterior segment of the eye
US11/444,349 US20070280902A1 (en) 2006-06-01 2006-06-01 Method for treating eye disease or conditions affecting the posterior segment of the eye
EP06290902A EP1864668B1 (en) 2006-06-01 2006-06-01 Use of prodrugs for ocular intravitreous administration
EP06290901.5A EP1864667B1 (en) 2006-06-01 2006-06-01 Use of prodrugs for ocular intravitreous administration

Publications (1)

Publication Number Publication Date
DK1864668T3 true DK1864668T3 (da) 2013-03-04

Family

ID=39712456

Family Applications (2)

Application Number Title Priority Date Filing Date
DK06290902.3T DK1864668T3 (da) 2006-06-01 2006-06-01 Anvendelse af prodrug til okulær, intravitreal administration
DK10177382.8T DK2319517T3 (da) 2006-06-01 2006-06-01 Anvendelse af prodrugs til okulær, intravenøs administration

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK10177382.8T DK2319517T3 (da) 2006-06-01 2006-06-01 Anvendelse af prodrugs til okulær, intravenøs administration

Country Status (15)

Country Link
US (4) US20070280902A1 (da)
EP (4) EP2319517B1 (da)
JP (2) JP5284953B2 (da)
KR (1) KR101408317B1 (da)
CN (1) CN101553235B (da)
AU (1) AU2007267079B2 (da)
CA (1) CA2653902C (da)
DK (2) DK1864668T3 (da)
ES (1) ES2399976T3 (da)
HK (2) HK1110219A1 (da)
IL (1) IL195626A (da)
PL (4) PL1864668T3 (da)
PT (2) PT1864668E (da)
SI (1) SI1864668T1 (da)
WO (2) WO2007138113A1 (da)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1864668T3 (da) 2006-06-01 2013-03-04 Novagali Pharma Sa Anvendelse af prodrug til okulær, intravitreal administration
HUE055815T2 (hu) * 2007-10-05 2021-12-28 Univ Wayne State Vegyületek nyújtott felszabadítására alkalmas dendrimerek
EP2564853B1 (en) * 2007-12-04 2019-02-27 Santen SAS Compositions comprising corticosteroid prodrug such as dexamethasone palmitate for the treatment of eye disorders
JP5591226B2 (ja) 2008-05-12 2014-09-17 ユニバーシティ・オブ・ユタ・リサーチ・ファウンデイション 眼内薬物送達装置および関連する方法
US9877973B2 (en) 2008-05-12 2018-01-30 University Of Utah Research Foundation Intraocular drug delivery device and associated methods
US9095404B2 (en) 2008-05-12 2015-08-04 University Of Utah Research Foundation Intraocular drug delivery device and associated methods
US10064819B2 (en) 2008-05-12 2018-09-04 University Of Utah Research Foundation Intraocular drug delivery device and associated methods
UA116622C2 (uk) * 2011-11-11 2018-04-25 Аллерган, Інк. Похідні 4-прегенен-11ss-17-21-тріол-3,20-діону для лікування хвороб очей
JP6231995B2 (ja) * 2012-02-10 2017-11-15 タイワン リポソーム カンパニー リミテッド 眼の疾患の合併症を低減するための薬学的組成物
US11433090B2 (en) 2017-06-16 2022-09-06 The Doshisha mTOR-inhibitor-containing medicine for treating or preventing ophthalmic symptoms, disorders, or diseases, and application thereof
CN111615528A (zh) 2017-11-10 2020-09-01 约翰霍普金斯大学 树枝状聚合物递送系统和其使用方法
CN111068071A (zh) * 2018-10-22 2020-04-28 武汉纽福斯生物科技有限公司 基因治疗Leber遗传学视神经病变
PL3871662T3 (pl) * 2020-02-25 2023-11-20 Labomed Pharmaceutical Company S.A. Doustne roztwory zawierające octan fludrokortyzonu
JP2023542435A (ja) 2020-09-16 2023-10-06 サンテン エスエーエス 硝子体内投与のための水中油型油エマルション

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS609726B2 (ja) * 1980-05-15 1985-03-12 株式会社 ミドリ十字 ステロイド製剤
JPS5716818A (en) * 1981-04-25 1982-01-28 Green Cross Corp:The Steroid fatty emulsion
AU531588B2 (en) 1981-08-17 1983-09-01 Yoshitomi Pharmaceutical Industries, Ltd. Emulsifying water-insoluble steroid
EP0244178A3 (en) 1986-04-28 1989-02-08 Iolab, Inc Intraocular dosage compositions and method of use
WO1990001933A1 (en) 1988-08-26 1990-03-08 Alcon Laboratories, Inc. Combination of quinolone antibiotics and steroids for topical ophthalmic use
JPH05132498A (ja) * 1991-11-08 1993-05-28 Asahi Glass Co Ltd ステロイド誘導体およびその製剤
IL101241A (en) * 1992-03-16 1997-11-20 Yissum Res Dev Co Pharmaceutical or cosmetic composition comprising stabilized oil-in-water type emulsion as carrier
CA2125060C (en) * 1993-07-02 1999-03-30 Henry P. Dabrowski Ophthalmic solution for artificial tears
US5792786A (en) * 1993-08-02 1998-08-11 Commonwealth Scientific And Industrial Research Organisation Non-steroidal anti-inflammatory fatty acid conjugates and their therapeutic use thereof
ES2094688B1 (es) 1994-08-08 1997-08-01 Cusi Lab Manoemulsion del tipo de aceite en agua, util como vehiculo oftalmico y procedimiento para su preparacion.
US6114319A (en) 1997-05-14 2000-09-05 Senju Pharmaceutical Co., Ltd. Compositions containing difluprednate
JP3410364B2 (ja) 1997-05-14 2003-05-26 千寿製薬株式会社 ジフルプレドナート含有組成物
IL121647A (en) * 1997-08-28 2001-07-24 Pharmateam Dev Ltd Pharmaceutical compositions for the treatment of ocular inflammation comprising dexamethasone palmitate
WO1999016471A1 (fr) * 1997-10-01 1999-04-08 Wakamoto Pharmaceutical Co., Ltd. Compositions d'emulsions de type aqueux
JP2000212067A (ja) * 1999-01-19 2000-08-02 Towa Yakuhin Kk 薬物含有エマルジョン製剤
CN100335036C (zh) 2001-11-01 2007-09-05 耶路撒冷希伯来语大学依苏姆研究开发公司 用于干眼症治疗的方法和组合物
US20040151754A1 (en) * 2002-12-20 2004-08-05 Control Delivery Systems, Inc. Steroid suspensions for intraocular use
US20050009910A1 (en) * 2003-07-10 2005-01-13 Allergan, Inc. Delivery of an active drug to the posterior part of the eye via subconjunctival or periocular delivery of a prodrug
CA2539741A1 (en) * 2003-09-22 2005-03-31 Bionetworks Gmbh Prevention and treatment of inflammation-induced and/or immune-mediated bone loss
US20050244469A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Extended therapeutic effect ocular implant treatments
US8119154B2 (en) * 2004-04-30 2012-02-21 Allergan, Inc. Sustained release intraocular implants and related methods
DE602004022523D1 (de) * 2004-07-02 2009-09-24 Novagali Pharma Sa Verwendung von Emulsionen zur intra- und periocularen Injection
BRPI0513243B8 (pt) * 2004-07-12 2021-05-25 Allergan Inc composições oftálmicas e respectivos usos
EP2452670A1 (en) * 2004-10-01 2012-05-16 Ramscor, Inc. Conveniently implantable sustained release drug compositions
US20060094700A1 (en) * 2004-11-02 2006-05-04 Allergan, Inc. Heat sterilization of a steroid in the presence of phosphate
CA2578176C (en) 2004-11-09 2013-09-24 Novagali Pharma Sa Ophthalmic emulsions containing an immunosuppressive agent
CN1905012A (zh) 2005-07-31 2007-01-31 新科实业有限公司 具有微驱动器的磁头折片组合及其磁盘驱动装置
US8109884B2 (en) * 2005-09-23 2012-02-07 Kitchener Clark Wilson Dynamic metabolism monitoring system
DK1864668T3 (da) 2006-06-01 2013-03-04 Novagali Pharma Sa Anvendelse af prodrug til okulær, intravitreal administration

Also Published As

Publication number Publication date
US20070280902A1 (en) 2007-12-06
IL195626A0 (en) 2009-09-01
JP2009538880A (ja) 2009-11-12
PT1864668E (pt) 2013-02-26
PL2322183T3 (pl) 2015-01-30
US9192567B2 (en) 2015-11-24
US20070280995A1 (en) 2007-12-06
JP2009538879A (ja) 2009-11-12
JP5284953B2 (ja) 2013-09-11
AU2007267079B2 (en) 2013-01-31
US20070281913A1 (en) 2007-12-06
PL2319517T3 (pl) 2014-01-31
JP5455624B2 (ja) 2014-03-26
CN101553235A (zh) 2009-10-07
AU2007267079A1 (en) 2007-12-06
ES2399976T3 (es) 2013-04-04
EP2319517B1 (en) 2013-09-11
CN101553235B (zh) 2012-12-05
EP1864668B1 (en) 2012-11-21
IL195626A (en) 2017-05-29
HK1110221A1 (en) 2008-07-11
EP1864668A1 (en) 2007-12-12
EP2322183B1 (en) 2014-10-22
WO2007138113A1 (en) 2007-12-06
HK1110219A1 (en) 2008-07-11
EP2322183A1 (en) 2011-05-18
CA2653902A1 (en) 2007-12-06
SI1864668T1 (sl) 2013-04-30
EP1864667A1 (en) 2007-12-12
WO2007138114A1 (en) 2007-12-06
PL1864668T3 (pl) 2013-04-30
CA2653902C (en) 2015-03-17
EP1864667B1 (en) 2013-09-04
US20070281914A1 (en) 2007-12-06
PT1864667E (pt) 2013-11-18
EP2319517A1 (en) 2011-05-11
US8227452B2 (en) 2012-07-24
DK2319517T3 (da) 2013-12-09
KR20090031373A (ko) 2009-03-25
KR101408317B1 (ko) 2014-06-17
PL1864667T3 (pl) 2014-01-31

Similar Documents

Publication Publication Date Title
DK1864668T3 (da) Anvendelse af prodrug til okulær, intravitreal administration
LTC1781298I2 (lt) Farmacinės kompozicijos, turinčios benzoksazino, skirtos respiracinių ligų gydymui
AP2378A (en) Sulfonamide derivatives for the treatment of diseases.
CU20080044A7 (es) Composiciones farmacéuticas para el tratamiento de trastornos del oído interno.
AP2359A (en) Sulfonamide derivatives for the treatment of diseases.
DK2474321T3 (da) Sammensætninger til behandling af collagenmedierede sygdomme
CL2007002641A1 (es) Compuestos derivados de pirimidinas; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de trastornos alergicos, autoinmunes, enfermedades inflamatorias.
DOP2005000025A (es) Compuestos de heteroaril- y fenilsulfamoilo sustituidos
DK1833799T3 (da) 3-phenyl-pyrazol derivater, som modulatorer af 5-HT-2a-serotonin receptor nyttig til behandlingen af sygdomme relateret hertil
HN2008000311A (es) Formas cristalinas de 4-metil-n-[3-(4-metil-imidazol-1-il)-5-trifluorometil-fenil]-3-(4-piridin-3-il-pirimidin-2-ilamino)-benzamida
DK2380584T3 (da) Immunstimulerende fremgangsmåde
BRPI0816881A2 (pt) Composto, composição farmacêutica, uso de um composto, e, métodos para tratar doenças ou distúrbios e para preparar um composto.
DE602006006712D1 (de) Thiazolylpiperidin-derivate nützlich als h3 rezeptor modulatoren
WO2009005794A3 (en) Alkynyl phenyl derivative compounds for treating ophthalmic diseases and disorders
WO2006081363A3 (en) Oral formulations for delivery of catecholic butanes including ndga compounds
WO2009071690A3 (de) 5,6-disubstituierte oxindol-derivate und ihre verwendung zur behandlung von vasopressin-abhängigen erkrankungen
WO2009071689A3 (de) 5-halogen-substituierte oxindol-derivate und ihre verwendung zur behandlung von vasopressin-abhängigen erkrankungen
CL2007002920A1 (es) Compuestos derivados de 2-aminocarbonilpiridina; composicion farmaceutica; y uso para el tratamiento de trastornos vasculares oclusivos.
NL1028599A1 (nl) Verbindingen voor de behandeling van ziekten.
DK2041093T3 (da) Til behandling af GPR38-receptor medierede sygdomme anvendelige piperazinylderivativer
DK2148667T3 (da) Anvendelse af cyclohexanhexolderivater til behandling af øjensygdomme
ECSP11010956A (es) Compuestos enlazados con azufre para el tratamiento de enfermedades y trastornos oftalmicos
CL2007002386A1 (es) Uso de compuestos derivados de 2,5-dihidroxibenceno para el tratamiento y/o profilaxis de enfermedades seleccionadas de degeneracion macular, neovascularizacion o angiogenesis de la cornea, iris o retina, retinopatia diabetica y no diabetica.
WO2007135426A3 (en) Treatment of neurodegeneratives diseases
ITRM20050179A1 (it) Composizione impiegabile per il trattamento delle patologie paradontali.